STAINES-UPON-THAMES, England,
Nov. 14, 2017 /PRNewswire/
-- Mallinckrodt Pharmaceuticals (NYSE: MNK), a leading global
specialty pharmaceutical company, will present on Thursday, Dec. 14, 2017, at the BMO Prescriptions
for Success Healthcare Conference, which takes place at the Westin
Grand Central New York, 212 East 42nd St, New York, NY.
Matthew Harbaugh, Executive Vice
President and Chief Financial Officer, and Dr. Steven Romano, Executive Vice President and
Chief Scientific Officer, will represent the company in a fireside
chat at 8 a.m. Eastern time.
Individuals who cannot attend the meeting in person can find
webcast information at: http://www.mallinckrodt.com/investors. A
replay will also be available following the meeting.
ABOUT MALLINCKRODT
Mallinckrodt is a global business that
develops, manufactures, markets and distributes specialty
pharmaceutical products and therapies. Areas of focus include
autoimmune and rare diseases in specialty areas like neurology,
rheumatology, nephrology, pulmonology and ophthalmology;
immunotherapy and neonatal respiratory critical care therapies; and
analgesics and hemostasis products. The company's core strengths
include the acquisition and management of highly regulated raw
materials and specialized chemistry, formulation and manufacturing
capabilities. The company's Specialty Brands segment includes
branded medicines and its Specialty Generics segment includes
specialty generic drugs, active pharmaceutical ingredients and
external manufacturing. To learn more about Mallinckrodt, visit www.mallinckrodt.com.
Mallinckrodt uses its website as a
channel of distribution of important company information, such as
press releases, investor presentations and other financial
information. It also uses its website to expedite public access to
time-critical information regarding the company in advance of or in
lieu of distributing a press release or a filing with the U.S.
Securities and Exchange Commission disclosing the same information.
Therefore, investors should look to the Investor Relations page of
the website for important and time-critical information. Visitors
to the website can also register to receive automatic e-mail and
other notifications alerting them when new information is made
available on the Investor Relations page of the website.
CONTACTS
Investor Relations
Coleman N.
Lannum, CFA
Senior Vice President, Investor Strategy and IRO
314-654-6649
cole.lannum@mallinckrodt.com
Daniel J. Speciale, CPA
Director, Investor Relations
314-654-3638
daniel.speciale@mallinckrodt.com
Media
Rhonda Sciarra
Senior Communications Manager
908-238-6765
rhonda.sciarra@mallinckrodt.com
Meredith Fischer
Chief Public Affairs Officer
314-654-3318
meredith.fischer@mallinckrodt.com
View original content with
multimedia:http://www.prnewswire.com/news-releases/mallinckrodt-to-present-at-the-bmo-prescriptions-for-success-healthcare-conference-300555135.html
SOURCE Mallinckrodt Pharmaceuticals